Prostate Cancer Managed with Active Surveillance: Role of Anatomic MR Imaging and MR Spectroscopic Imaging

被引:101
|
作者
Fradet, Vincent [2 ]
Kurhanewicz, John [1 ]
Cowan, Janet E. [2 ]
Karl, Alexander [2 ]
Coakley, Fergus V. [2 ]
Shinohara, Katsuto [2 ]
Carroll, Peter R. [2 ]
机构
[1] Univ Calif San Francisco, Dept Radiol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Urol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
基金
美国国家卫生研究院;
关键词
ENDORECTAL MR; INCREMENTAL VALUE; TUMOR; MEN; PREDICTION; ANTIGEN; LOCALIZATION; SUPPRESSION; BIOPSY; MARKER;
D O I
10.1148/radiol.10091147
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To determine the role that magnetic resonance (MR) imaging and MR spectroscopic imaging findings obtained at the time of diagnosis play in the progression of disease in patients whose prostate cancer is being managed with active surveillance and to compare the role of these findings with the role of transrectal ultrasonography (US) findings. Materials and Methods: The institutional review board approved this HIPAA-compliant retrospective study, and informed consent was obtained from all patients whose records were to be entered into the research database. All patients who had prostate cancer managed with active surveillance and who had undergone both MR imaging and MR spectroscopic imaging of the prostate and transrectal US at time of diagnosis were identified. Two urologists blinded to the clinical outcome in these patients independently reviewed and dichotomized the MR imaging report and the MR spectroscopic imaging report as normal or suggestive of malignancy. One experienced urologist performed all US examinations that were then dichotomized similarly. Uni- and multivariate (with use of standard clinical variables) Cox models were fitted to assess time to cancer progression, defined as Gleason score upgrading, prostate-specific antigen velocity of more than 0.75 (mu g . L-1)/y, or initiation of treatment more than 6 months after diagnosis. Results: The final cohort included 114 patients with a median follow-up of 59 months. Patients with a lesion that was suggestive of cancer at MR imaging had a greater risk of the Gleason score being upgraded at subsequent biopsy (hazard ratio, 4.0; 95% confidence interval: 1.1, 14.9) than did patients without such a lesion. Neither MR spectroscopic imaging nor transrectal US could be used to predict cancer progression. Conclusion: Abnormal prostate MR imaging results suggestive of cancer may confer an increased risk of Gleason score upgrade at subsequent biopsy. Although expensive, prostate MR imaging may help in counseling potential candidates about active surveillance. (C) RSNA, 2010
引用
收藏
页码:176 / 183
页数:8
相关论文
共 50 条
  • [1] MR Imaging for Prostate Cancer Screening and Active Surveillance
    Druskin, Sasha C.
    Macura, Katarzyna J.
    [J]. RADIOLOGIC CLINICS OF NORTH AMERICA, 2018, 56 (02) : 251 - +
  • [2] Role of endorectal MR and MR spectroscopic imaging in the diagnosis of prostate cancer
    Costouros, NG
    Coakley, FV
    Qayyum, A
    Yeh, BM
    Joe, BN
    Kurhanewicz, J
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2005, 184 (04) : 62 - 62
  • [3] Active Surveillance for Prostate Cancer Expanding the Role of MR Imaging and the Use of PRECISE Criteria
    Englman, Cameron
    Barrett, Tristan
    Moore, Caroline M.
    Giganti, Francesco
    [J]. RADIOLOGIC CLINICS OF NORTH AMERICA, 2024, 62 (01) : 69 - 92
  • [4] MR spectroscopic imaging for evaluation of prostate cancer
    Taouli, B
    [J]. JOURNAL DE RADIOLOGIE, 2006, 87 (02): : 222 - 227
  • [5] Prostate cancer tumor volume: Measurement by endorectal MR imaging and MR spectroscopic imaging
    Coakley, FV
    Kurhanewicz, J
    Lu, Y
    Jones, KD
    Swanson, MG
    Chang, SD
    [J]. RADIOLOGY, 2001, 221 : 585 - 585
  • [6] Prostate cancer: Is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance?
    Cabrera, Alvin R.
    Coakley, Fergus V.
    Westphalen, Antonio C.
    Lu, Ying
    Zhao, Shoujun
    Shinohara, Katsuto
    Carroll, Peter R.
    Kurhanewicz, John
    [J]. RADIOLOGY, 2008, 247 (02) : 444 - 450
  • [7] Endorectal MR imaging and spectroscopic imaging of transition zone prostate cancer
    Eberhardt, SC
    Coakley, FV
    Schwartz, LH
    Zakian, KL
    Heinze, SB
    Hricak, H
    [J]. RADIOLOGY, 2001, 221 : 584 - 585
  • [8] Developments in proton MR spectroscopic imaging of prostate cancer
    Stamatelatou, Angeliki
    Scheenen, Tom W. J.
    Heerschap, Arend
    [J]. MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE, 2022, 35 (04) : 645 - 665
  • [9] Developments in proton MR spectroscopic imaging of prostate cancer
    Angeliki Stamatelatou
    Tom W. J. Scheenen
    Arend Heerschap
    [J]. Magnetic Resonance Materials in Physics, Biology and Medicine, 2022, 35 : 645 - 665
  • [10] Multidimensional MR spectroscopic imaging of prostate cancer in vivo
    Thomas, M. Albert
    Nagarajan, Rajakumar
    Huda, Amir
    Margolis, Daniel
    Sarma, Manoj K.
    Sheng, Ke
    Reiter, Robert E.
    Raman, Steven S.
    [J]. NMR IN BIOMEDICINE, 2014, 27 (01) : 53 - 66